These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 11175492

  • 1. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA.
    Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M, Sharma DR, Singh V, Panwar RB, Hira HS, Mohan B, Kumar N, Sharma SK, Gupta R.
    Vasc Health Risk Manag; 2006 Feb; 2(1):87-93. PubMed ID: 17319473
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of extended-release niacin on lipoprotein subclass distribution.
    Morgan JM, Capuzzi DM, Baksh RI, Intenzo C, Carey CM, Reese D, Walker K.
    Am J Cardiol; 2003 Jun 15; 91(12):1432-6. PubMed ID: 12804729
    [Abstract] [Full Text] [Related]

  • 6. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA.
    Metabolism; 2008 Jun 15; 57(6):796-801. PubMed ID: 18502262
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
    Crouse JR.
    Coron Artery Dis; 1996 Apr 15; 7(4):321-6. PubMed ID: 8853585
    [Abstract] [Full Text] [Related]

  • 9. Antioxidants blunt high-density lipoprotein response to statin plus niacin therapy.
    Kris-Etherton PM.
    Curr Atheroscler Rep; 2001 Nov 15; 3(6):435-6. PubMed ID: 11602062
    [No Abstract] [Full Text] [Related]

  • 10. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes.
    Pan J, Lin M, Kesala RL, Van J, Charles MA.
    Diabetes Obes Metab; 2002 Jul 15; 4(4):255-61. PubMed ID: 12099974
    [Abstract] [Full Text] [Related]

  • 11. Niacin as a component of combination therapy for dyslipidemia.
    Miller M.
    Mayo Clin Proc; 2003 Jun 15; 78(6):735-42. PubMed ID: 12934785
    [Abstract] [Full Text] [Related]

  • 12. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD.
    Arch Intern Med; 2000 Apr 24; 160(8):1177-84. PubMed ID: 10789612
    [Abstract] [Full Text] [Related]

  • 13. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J, Van JT, Chan E, Kesala RL, Lin M, Charles MA.
    Metabolism; 2002 Sep 24; 51(9):1120-7. PubMed ID: 12200755
    [Abstract] [Full Text] [Related]

  • 14. Niacin and lipoprotein(a): facts, uncertainties, and clinical considerations.
    Scanu AM, Bamba R.
    Am J Cardiol; 2008 Apr 17; 101(8A):44B-47B. PubMed ID: 18375241
    [Abstract] [Full Text] [Related]

  • 15. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
    Krüger B.
    Int J Clin Pharmacol Res; 1994 Apr 17; 14(5-6):177-83. PubMed ID: 7672874
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H, Giezek H, McKenney JM, O'Neill EA, Tershakovec AM.
    Metab Syndr Relat Disord; 2012 Aug 09; 10(4):260-6. PubMed ID: 22400810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.